Safety and Efficacy of Mosunetuzumab: Experience in the A.O. Card G. Panico

Follicular lymphoma (FL) is the second most common form of non-Hodgkin’s lymphoma (NHL) and accounts for about 5% of all hematological malignancies. Despite therapeutic advances, FL follicular lymphoma remains an incurable disease, with frequent relapses and increasingly shorter disease control intervals. Bispecific antibodies (bsAbs) are molecules that target two different epitopes or antigens. The mechanism of action is determined by the molecular targets and structure of the bsAbs. Several bsAbs have already changed the therapeutic landscape of hematological malignancies and some solid tumors. In particular, in this article we review the general principles on follicular lymphoma and established and innovative therapies including bsAbs, in particular the bsAb mosunetuzumab, a new bispecific antibody that acts on CD3 epitopes of T lymphocytes and CD20 epitopes of B lymphocytes with the aim of inducing T lymphocyte-mediated elimination of malignant B lymphocytes, its safety and efficacy with the analysis of no. 3 patients who completed treatment with the drug mosunetuzumab in the A.O. Pia Fondazione di Culto e Religione ‘Card. G. Panico’, Tricase (Lecce).